167 related articles for article (PubMed ID: 20332524)
1. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.
Baghdasaryan A; Claudel T; Kosters A; Gumhold J; Silbert D; Thüringer A; Leski K; Fickert P; Karpen SJ; Trauner M
Gut; 2010 Apr; 59(4):521-30. PubMed ID: 20332524
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression.
Patsenker E; Popov Y; Stickel F; Jonczyk A; Goodman SL; Schuppan D
Gastroenterology; 2008 Aug; 135(2):660-70. PubMed ID: 18538673
[TBL] [Abstract][Full Text] [Related]
3. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
Nishio T; Hu R; Koyama Y; Liang S; Rosenthal SB; Yamamoto G; Karin D; Baglieri J; Ma HY; Xu J; Liu X; Dhar D; Iwaisako K; Taura K; Brenner DA; Kisseleva T
J Hepatol; 2019 Sep; 71(3):573-585. PubMed ID: 31071368
[TBL] [Abstract][Full Text] [Related]
4. Endothelin Receptor-A Inhibition Decreases Ductular Reaction, Liver Fibrosis, and Angiogenesis in a Model of Cholangitis.
Owen T; Carpino G; Chen L; Kundu D; Wills P; Ekser B; Onori P; Gaudio E; Alpini G; Francis H; Kennedy L
Cell Mol Gastroenterol Hepatol; 2023; 16(4):513-540. PubMed ID: 37336290
[TBL] [Abstract][Full Text] [Related]
5. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
6. Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice.
Latasa MU; Gil-Puig C; Fernández-Barrena MG; Rodríguez-Ortigosa CM; Banales JM; Urtasun R; Goñi S; Méndez M; Arcelus S; Juanarena N; Recio JA; Lotersztajn S; Prieto J; Berasain C; Corrales FJ; Lecanda J; Avila MA
PLoS One; 2010 Dec; 5(12):e15690. PubMed ID: 21209952
[TBL] [Abstract][Full Text] [Related]
7. Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 -/- mice.
Wu N; Zhou T; Carpino G; Baiocchi L; Kyritsi K; Kennedy L; Ceci L; Chen L; Wu C; Kundu D; Barupala N; Franchitto A; Onori P; Ekser B; Gaudio E; Francis H; Glaser S; Alpini G
Hepatology; 2023 Jun; 77(6):1849-1865. PubMed ID: 36799446
[TBL] [Abstract][Full Text] [Related]
8. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
Zhang J; Lyu Z; Li B; You Z; Cui N; Li Y; Li Y; Huang B; Chen R; Chen Y; Peng Y; Fang J; Wang Q; Miao Q; Tang R; Gershwin ME; Lian M; Xiao X; Ma X
Hepatology; 2023 Jul; 78(1):10-25. PubMed ID: 36799463
[TBL] [Abstract][Full Text] [Related]
9. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice.
Gonzalez-Sanchez E; El Mourabit H; Jager M; Clavel M; Moog S; Vaquero J; Ledent T; Cadoret A; Gautheron J; Fouassier L; Wendum D; Chignard N; Housset C
Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166067. PubMed ID: 33418034
[TBL] [Abstract][Full Text] [Related]
10. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.
Tabibian JH; O'Hara SP; Trussoni CE; Tietz PS; Splinter PL; Mounajjed T; Hagey LR; LaRusso NF
Hepatology; 2016 Jan; 63(1):185-96. PubMed ID: 26044703
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.
Stiedl P; McMahon R; Blaas L; Stanek V; Svinka J; Grabner B; Zollner G; Kessler SM; Claudel T; Müller M; Mikulits W; Bilban M; Esterbauer H; Eferl R; Haybaeck J; Trauner M; Casanova E
Hepatology; 2015 Feb; 61(2):613-26. PubMed ID: 25179284
[TBL] [Abstract][Full Text] [Related]
12. GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2
Fuchs CD; Claudel T; Mlitz V; Riva A; Menz M; Brusilovskaya K; Haller F; Baumgartner M; Königshofer P; Unger LW; Sjöland W; Scharnagl H; Stojakovic T; Busslinger G; Reiberger T; Marschall HU; Trauner M
Cell Mol Gastroenterol Hepatol; 2023; 16(5):847-856. PubMed ID: 37572734
[TBL] [Abstract][Full Text] [Related]
13. ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.
O'Hara SP; Splinter PL; Trussoni CE; Pisarello MJ; Loarca L; Splinter NS; Schutte BF; LaRusso NF
J Biol Chem; 2017 Mar; 292(12):4833-4846. PubMed ID: 28184004
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.
Loarca L; De Assuncao TM; Jalan-Sakrikar N; Bronk S; Krishnan A; Huang B; Morton L; Trussoni C; Bonilla LM; Krueger E; O'Hara S; Splinter P; Shi G; Pisarello MJL; Gores GJ; Huebert RC; LaRusso NF
Lab Invest; 2017 Nov; 97(11):1385-1396. PubMed ID: 28892096
[TBL] [Abstract][Full Text] [Related]
15. Telomere dysfunction promotes cholangiocyte senescence and biliary fibrosis in primary sclerosing cholangitis.
Jalan-Sakrikar N; Anwar A; Yaqoob U; Gan C; Lagnado AB; Wixom AQ; Jurk D; Huebert RC
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37707950
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis.
Shi T; Malik A; Yang Vom Hofe A; Matuschek L; Mullen M; Lages CS; Kudira R; Singh R; Zhang W; Setchell KDR; Hildeman D; Pasare C; Wagner B; Miethke AG
Sci Transl Med; 2022 Dec; 14(675):eabi4354. PubMed ID: 36516265
[TBL] [Abstract][Full Text] [Related]
17. A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway.
Islam D; Israr I; Taleb MAB; Rao A; Yosief R; Sultana R; Sampaziotis F; Tysoe OC; Trauner M; Karpen SJ; Ghanekar A; Kamath BM
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407207
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
Kellerer M; Javed S; Casar C; Will N; Berkhout LK; Schwinge D; Krebs CF; Schramm C; Neumann K; Tiegs G
Hepatology; 2024 Mar; ():. PubMed ID: 38441998
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.
Tabibian JH; O'Hara SP; Splinter PL; Trussoni CE; LaRusso NF
Hepatology; 2014 Jun; 59(6):2263-75. PubMed ID: 24390753
[TBL] [Abstract][Full Text] [Related]
20. Beta-lapachone ameliorates the progression of primary sclerosing cholangitis pathogenesis in rodent models.
Woo SH; Lee SH; Moon SJ; Han J; Seo KS; Lee H; Lee CH; Hwang JH
Life Sci; 2024 Jan; 337():122342. PubMed ID: 38092141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
